There will be a patent dispute over the osteoporosis drug Bonviva (Ibandronate) again.

It is an analysis of damages worth ₩tens of billions by domestic companies that are selling generics for Bonviva.

According to the pharmaceutical industry on the 10th, British pharmaceutical company Atnahs Pharma, which owns patents of Bonviva, recently filed a lawsuit with the Patent Court to cancel the verdict of The Intelligent Property Trial and Appeal Board.

In the previous first trial, Atnahs Pharma was defeated. The Intelligent Property Trial and Appeal Board ruled in March that Bonviva's patent was invalid.

South Korean companies launched generic for Bonviva i